SCHEMBL5982851

SCHEMBL5982851

CC1(C)O[C@@H]2O[C@@H](COCc3ccccc3)[C@H](OCc3ccccc3)[C@H]2O1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ TACR2 P21452 3/20 0.45
▸ NT5E P21589 1/20 0.43
▸ SSTR1 P30872 1/20 0.42
▸ SSTR2 P30874 1/20 0.42
▸ SSTR4 P31391 1/20 0.42
▸ SSTR3 P32745 1/20 0.42
▸ SSTR5 P35346 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ GJB2 P29033 2/20 0.41
▸ BCHE P06276 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ PTPN1 P18031 2/20 0.39
▸ CDC25B P30305 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18817528 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL17039969 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL3229210 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL24371984 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL12896363 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL23989119 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL1058424 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL20789103 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL20805258 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1
SCHEMBL13430412 1.00 HTR1A (0.46) HTR1AALDH1A1TACR2NT5ESSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634888-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2006-03-15 — — EP disclosed
EP-1600452-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2005-11-30 — — EP disclosed
EP-1600451-A2 Synthesis of 2'-deoxy-l-nucleosides Pharmasset Limited (US) 2005-11-30 — — EP disclosed
US-20050090660-A1 2'-deoxy-L-nucleosides PHARMASSET, INC. 2005-04-28 — — US disclosed
EP-1232166-A2 SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES Pharmasset Limited (US) 2002-08-21 — — EP disclosed
WO-2001034618-A2 SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES PHARMASSET LIMITED (US) 2001-05-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090660-A1 2'-deoxy-L-nucleosides CCNH, ADAR, NSUN2 HTR1A 3162/4885ALDH1A1 4093/4885TACR2 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback